litlas
Log inCreate account

Ana Arance

Active 2000–2025

121
Papers
35,751
Citations
62
h-index
103
i10-index

Citations

Citations per year for Ana Arance2001: 4 citations2002: 1 citations2003: 1 citations2004: 6 citations2005: 9 citations2006: 2 citations2007: 6 citations2008: 3 citations2009: 2 citations2010: 6 citations2011: 1 citations2012: 1 citations2013: 6 citations2014: 31 citations2015: 251 citations2016: 543 citations2017: 642 citations2018: 694 citations2019: 1,983 citations2020: 2,153 citations2021: 2,027 citations2022: 1,806 citations2023: 1,338 citations2024: 2,147 citations2025: 949 citations2026: 23 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,947 citing papers, 24.4% of this breakdownChina: 1,805 citing papers, 11.1% of this breakdownGermany: 990 citing papers, 6.1% of this breakdownItaly: 989 citing papers, 6.1% of this breakdownFrance: 883 citing papers, 5.5% of this breakdownUnited Kingdom: 825 citing papers, 5.1% of this breakdownAustralia: 713 citing papers, 4.4% of this breakdownSpain: 554 citing papers, 3.4% of this breakdownNetherlands: 551 citing papers, 3.4% of this breakdownJapan: 506 citing papers, 3.1% of this breakdownCanada: 470 citing papers, 2.9% of this breakdownSwitzerland: 466 citing papers, 2.9% of this breakdown
0%24.4%Other 21.6%

Institutions

Fields

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology7.2%
  • Neuroscience2.1%
  • Engineering1%
  • Computer Science0.6%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers18.2%
  • Immunotherapy and Immune Responses7.2%
  • Melanoma and MAPK Pathways6.5%
  • CAR-T cell therapy research6.3%
  • Cutaneous Melanoma Detection and Management4.7%
  • Immune Cell Function and Interaction3%
  • Other54.1%

Coauthors

All papers

Open in search
  1. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

    Authors: Hussein A. Tawbi, Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, Sarah Keidel, Katy L. Simonsen, Anne Marie Sobiesk, Bin Li, F. Stephen Hodi, Georgina V. Long - New England Journal of Medicine 2022 cited by 1,759

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas - New England Journal of Medicine 2015 cited by 5,847

  3. Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Authors: Caroline Robert, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona M. McNeil, Ewa Kalinka‐Warzocha, Kerry J. Savage, Micaela Hernberg, Célèste Lebbé, J. Charles, Catalin Mihalcioiu, Vanna Chiarion‐Sileni, Cornelia Mauch, Francesco Cognetti, Ana Arance, Henrik Schmidt, Dirk Schadendorf, Helen Gogas, L. Lundgren-Eriksson, Christine E. Horak, Brian J. Sharkey, Ian M. Waxman, Victoria Atkinson, Paolo A. Ascierto - New England Journal of Medicine 2014 cited by 5,352

  4. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Authors: Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell - The Lancet Oncology 2019 cited by 944

  5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Authors: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 cited by 2,207

  6. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Authors: Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Shu-Chih Su, Clemens Krepler, Nageatte Ibrahim, Georgina V. Long - The Lancet Oncology 2019 cited by 1,153

  7. Clinical implications of the intrinsic molecular subtypes of breast cancer

    Authors: Aleix Prat, Estela Pineda, Bárbara Adamo, Patricia Galván, Aranzazu Fernández-Martínez, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz-Mateu - The Breast 2015 cited by 1,310

  8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Authors: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 cited by 1,016

  9. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 cited by 1,871

  10. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Authors: Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Teresa M. Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert - The Lancet 2017 cited by 1,239

  11. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Authors: Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Célèste Lebbé, Hildur Helgadóttir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio Maria Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion‐Sileni - Journal of Clinical Oncology 2022 cited by 220

  12. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Authors: Michael A. Davies, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Keith T. Flaherty, Ana Arance, Vanna Chiarion‐Sileni, L. Thomas, Thierry Lesimple, Laurent Mortier, Stergios J. Moschos, David Hogg, Iván Márquez‐Rodas, Michele Del Vecchio, Célèste Lebbé, Nicolás Meyer, Ying Zhang, Yingjie Huang, Bijoyesh Mookerjee, Georgina V. Long - The Lancet Oncology 2017 cited by 775

  13. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    Authors: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 cited by 525

  14. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 cited by 1,386

  15. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    Authors: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 cited by 180

  16. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

    Authors: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi - NEJM Evidence 2023 cited by 124

  17. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma

    Authors: Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo A. Ascierto - Journal of Clinical Oncology 2022 cited by 185

  18. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

    Authors: Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, Andrew Mant, Muhammad A. Khattak, Catalin Mihalcioiu, Sekwon Jang, C. Lance Cowey, Alan D. Smith, Natalyn Hawk, Ke Chen, Scott J. Diede, Clemens Krepler, Georgina V. Long - Journal of Clinical Oncology 2022 cited by 127

  19. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - Journal of Clinical Oncology 2022 cited by 163

  20. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean‐Jacques Grob, Nicolás Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steve Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - 2022 cited by 146

  21. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

    Authors: Caroline Robert, Matteo S. Carlino, Catriona M. McNeil, Antoni Ribas, Jean‐Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, Arnold Blaustein, Michal Lotem, Ana Arance, Adil Daud, Omid Hamid, James Larkin, James R. Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long - Journal of Clinical Oncology 2023 cited by 113

  22. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

    Authors: G.V. Long, K.T. Flaherty, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, Vanna Chiarion‐Sileni, C. Lebbe, M. Mandalá, M. Millward, Ana Arance, Igor Bondarenko, J.B.A.G. Haanen, J. Hansson, Jochen Utikal, Virginia Ferraresi, P. Mohr, V. Probachai, Dirk Schadendorf, Paul Nathan, C. Robert, A. Ribas, M.A. Davies, S.R. Lane, J.J. Legos, B. Mookerjee, Jean‐Jacques Grob - Annals of Oncology 2017 cited by 652

  23. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    Authors: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 cited by 586

  24. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Authors: Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà, L. Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L. Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V. Long, Keith T. Flaherty - The Lancet Oncology 2017 cited by 491